Public Employees Retirement System of Ohio Invests $2.17 Million in Smith & Nephew SNATS, Inc. $SNN

Public Employees Retirement System of Ohio bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 34,605 shares of the medical equipment provider’s stock, valued at approximately $2,170,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SNN. BlackRock Inc. acquired a new stake in shares of Smith & Nephew SNATS during the 2nd quarter valued at $505,323,000. Bank of America Corp DE acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter worth $97,223,000. Bank of New York Mellon Corp acquired a new stake in shares of Smith & Nephew SNATS during the second quarter worth $89,325,000. Caisse de depot et placement du Quebec acquired a new stake in shares of Smith & Nephew SNATS during the second quarter worth $64,186,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares during the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Barclays cut Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. Zacks Research cut shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Weiss Ratings upgraded shares of Smith & Nephew SNATS from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday. Finally, Canaccord Genuity Group decreased their price objective on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. One research analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $30.93.

Smith & Nephew SNATS Stock Up 0.1%

Shares of Smith & Nephew SNATS stock opened at $28.91 on Monday. Smith & Nephew SNATS, Inc. has a 1 year low of $28.48 and a 1 year high of $38.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. The stock has a 50-day moving average price of $30.11 and a 200 day moving average price of $31.42.

Smith & Nephew SNATS Announces Dividend

The firm also recently announced a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a $0.312 dividend. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.